Elon Musk’s Neuralink’s Animal-Testing Panel Membership Raises Questions About Potential Violations

Elon Musk’s brain-implant venture has filled an animal-research oversight board with company insiders who may stand to benefit financially as the firm reaches development goals, according to company documents and interviews with six current and former employees.

Such oversight boards are required by federal law for organizations experimenting on certain types of animals. The panels are charged with ensuring proper animal care, high research standards, and the reliability of data that helps regulators decide whether drugs or medical devices are safe for human testing.

The membership of the panel at Musk‘s company, Neuralink, raises questions about potential violations of conflict-of-interest regulations aimed at protecting research integrity, a dozen animal-research and bioethics experts told Reuters. Neuralink is conducting animal experiments as it seeks regulatory approval for human trials of a brain chip intended to help paralyzed people type with their minds, among other ambitious goals.

Nineteen of the board’s 22 members were Neuralink employees as of late 2022, according to a company document reviewed by Reuters. The oversight board’s chair was the Neuralink executive who led the company’s animal-care program, and at least 11 other members were employees directly involved with animal care or research.

Details of the panel’s membership and its potential conflicts have not been previously reported. Insight into its makeup comes in the wake of two federal investigations, first reported by Reuters, into potential animal-welfare violations by Neuralink and allegations that it improperly transported dangerous pathogens on implants removed from monkey brains. Reuters reported in December that some employees had grown concerned about the animal experiments being rushed under pressure from Musk to speed development, causing needless suffering and deaths of pigs, sheep and monkeys.

It’s possible the board’s membership has changed since late last year. Musk and Neuralink didn’t respond to requests for comment for this story or previous Reuters articles about the investigations into its animal testing.

The review boards are known as “institutional animal care and use committees,” or IACUCs. The animal-research and bioethics experts said it’s rare for IACUCs to include employees with such direct financial stakes in the research outcome. Putting employees on such panels poses a particular problem at startups such as Neuralink because they tend to focus on a single breakthrough product and commonly reward employees with volatile company shares.

Neuralink staffers typically are compensated with salary and stock-based incentives, according to five current and former employees and Neuralink job advertisements reviewed by Reuters. Two of the staffers said some senior-level employees stand to make millions of dollars if the company secures critical regulatory approvals. Reuters couldn’t determine the compensation terms of the Neuralink IACUC members who are also company employees.

Neuralink shareholders could see big gains if the private company’s valuation, currently more than $1 billion, continues to soar. Successful animal trials are critical for the company to gain federal approval for human trials and, ultimately, brain-implant commercialization. Reuters reported in March that the U.S. Food and Drug Administration rejected Neuralink’s first human-trial application, in part because the company had not proven the device’s safety in animal tests.

Dr. Miguel Nicolelis, a neuroscientist and physician, has conducted brain-implant research at Duke University for nearly three decades. He said the IACUC members overseeing his animal experiments never had any role in the research, including animal tests of the same type Neuralink is conducting now. The independence of such boards, Nicolelis said, is critical to protecting the integrity of animal research that could impact humans in future clinical trials.

“It’s an obvious conflict of interest,” he said of the Neuralink board’s composition.

Rocky Partnership

Many companies outsource animal testing and oversight to universities or research institutes with strict rules to prevent such conflicts of interest, the animal-research and bioethics experts said. These institutions generally prohibit people with direct financial interests from serving on IACUCs or voting on animal experiments.

Neuralink originally partnered with the University of California, Davis, to help conduct and oversee its animal tests. But the company later ditched the university after a dispute, viewing the school’s processes as too slow and bureaucratic, one current and one former Neuralink staffer said. Neuralink then brought the research and oversight in-house.

UC Davis declined to comment on Neuralink’s new oversight board but said in a statement that its conflict-of-interest rules prohibit “interested” parties from voting or “influencing decisions” on such panels.

The US National Institutes of Health is the world’s largest public funder of biomedical research. On projects it backs, the agency bars any IACUC member deriving income or stock from a research sponsor from reviewing or voting on that sponsor’s animal research, said Dr. Patricia Brown, the director of the NIH’s Office of Laboratory Animal Welfare.

The NIH declined to comment on Neuralink’s board. The agency once reached out to Neuralink to offer funding and guidance under a program intended to boost brain-implant research, Reuters previously reported. Neuralink wasn’t interested in NIH funding because Musk wanted to avoid public oversight and perceived bureaucratic hurdles.

The US Department of Agriculture (USDA) is the lead agency enforcing animal-welfare regulations. The animal-research experts interviewed by Reuters, including two former top USDA officials, described the agency’s overall enforcement of conflict-of-interest rules as lax.

USDA regulations forbid IACUC members from participating in the “review or approval of an activity in which that member has a conflicting interest.” But that rule doesn’t clearly define a conflict. It does offer, as one example, a situation in which a board member is “personally involved in the activity.”

The USDA has interpreted the rule narrowly, the experts and former agency officials said. The agency, they said, rarely flags a conflict unless an IACUC member votes to approve a particular experiment the member is also directly running as a company employee. Beyond that, the USDA allows a range of potential conflicts that would never be permitted in human trials, which are overseen by other federal agencies that have similar conflict-of-interest regulations, the experts said. Conflicts such as the ones on Neuralink’s IACUC also are typically prohibited or avoided in animal trials by universities, research institutes and many companies.

In response to an inquiry from Reuters, the USDA said it had found no conflicts of interest on Neuralink’s board when the department inspected its animal-research operations during 10 inspections since 2020. The company has passed all inspections with no citations, according to public records and a person with knowledge of the examinations.

The agency declined to answer detailed questions about its legal interpretation or enforcement of conflict-of-interest rules for animal research and oversight.

The USDA’s Office of Inspector General, the agency now probing potential animal-welfare violations by Neuralink, is also investigating allegedly slipshod Animal Welfare Act enforcement by the USDA itself, in a joint probe with the U.S. Department of Justice, Reuters has reported.

The USDA and Justice Department declined to comment on the investigation. The USDA inspector general didn’t respond to requests for comment.

The joint probe is examining the agency’s oversight of Neuralink and of animal welfare more broadly. The investigation follows a long history of USDA OIG reports, including three since 2014, blasting the agency’s animal-welfare enforcement as ineffective. One issue is a stretched staff: The USDA employs 122 inspectors to inspect 11,785 facilities, ranging from zoos and breeders to labs, according to a Congressional Research Service report last July.

USDA enforcement of conflict-of-interest rules is rare. In more than 11,000 USDA inspections over the past decade, the agency issued eight citations for conflicts at research labs, none of which resulted in a penalty, according to a review of the records by Delcianna Winders, who oversees the Animal Law and Policy Institute at the Vermont Law and Graduate School. The lack of enforcement, she said, poses a serious risk that conflicted IACUC members will put their own interests before those of the animals.

“The USDA is really only inspecting paperwork and not looking under the hood,” she said. The case of Neuralink’s board, she said, illustrates the problem with “the overly narrow interpretation the USDA is giving to ‘conflicting interest.’”

Animal Welfare ‘Incident’

Between September 2017 and December 2020, Neuralink partnered with the University of California, Davis, relying on the school’s federally funded primate-research lab and its established IACUC. UC Davis received more than $1.9 million (nearly. Rs. 15 crore) from Neuralink for experiments before the partnership ended, the university said. Neuralink surgeons and other staffers continued to work directly on the experiments, in consultation with the university.

A UC Davis spokesperson told Reuters the university’s monitoring of Neuralink’s experiments detected an animal-welfare incident in 2019, prompting the university’s IACUC to mandate changes in Neuralink’s research protocols and training. The spokesperson said the incident didn’t involve UC Davis staff but declined to comment further.

Amid tensions, Neuralink canceled its partnership with UC Davis in 2020, then built its own animal-testing facilities and created its own IACUC.

Neuralink’s IACUC is charged with limiting the number of animals tested to the minimum required for research. Tested animals are typically killed after experiments so researchers can examine them post-mortem.

The company has rushed and at times botched experiments, especially after it brought animal experiments fully in-house, according to Neuralink staffers and company records seen by Reuters. The company’s IACUC allowed Neuralink to accelerate animal experiments, in line with Musk’s demands, three sources familiar with the panel’s decisions told Reuters.

In 2021 and 2022, the company killed about 250 sheep, pigs and primates, the company records show. In one instance in 2021, the company implanted 25 out of 60 pigs with the wrong-sized devices, Reuters previously reported. Neuralink employees said the error could have been avoided with better preparation.

Several animal-research experts called the role of board chair Autumn Sorrells — also the executive heading Neuralink’s animal-care program — a particularly troubling conflict.

Sorrells didn’t respond to requests for comment.

Several of the 22 IACUC members also report to Sorrells in their Neuralink jobs, separate from the board, according to internal documents and two Neuralink sources with knowledge of the committee’s operations. This dynamic discourages those members from dissenting in board matters, one of the sources said.

Neuralink never disclosed other IACUC members’ close connections to Sorrells to USDA inspectors during an inspection in January that was prompted by the December Reuters report and related scrutiny from US Congress members, according to a federal official with knowledge of the agency’s dealings with Neuralink. Inspectors likely would have examined the potential conflicts more closely if those connections were disclosed, the official said.

© Thomson Reuters 2023  
 


Smartphone companies have launched many compelling devices over the first quarter of 2023. What are some of the best phones launched in 2023 you can buy today? We discuss this on Orbital, the Gadgets 360 podcast. Orbital is available on Spotify, Gaana, JioSaavn, Google Podcasts, Apple Podcasts, Amazon Music and wherever you get your podcasts.
Affiliate links may be automatically generated – see our ethics statement for details.

Check out our Latest News and Follow us at Facebook

Original Source

Neuralink Said to Approach US Neurosurgery Centre as Potential Human Clinical Trials Partner

Elon Musk‘s brain implant company Neuralink has approached one of the biggest US neurosurgery centers as a potential clinical trials partner as it prepares to test its devices on humans once regulators allow for it, according to six people familiar with the matter.

Neuralink has been developing brain implants since 2016 it hopes will eventually be a cure for intractable conditions such as paralysis and blindness.

It suffered a blow in early 2022, when the US Food and Drug Administration rejected its application to progress to human trials, citing major safety concerns, Reuters reported earlier this month.

The company has since been working to address the agency’s concerns, and it is unclear if and when it will be successful.

Neuralink has been talking to Barrow Neurological Institute, a Phoenix, Arizona-based neurological disease treatment and research organization, to help carry out the human trials, the sources said.

The talks may not result in a team-up. Neuralink has also discussed partnering with other centers, added the sources, who requested anonymity to discuss the confidential deliberations.

Reuters could not verify the latest status of the talks. Neuralink representatives did not respond to requests for comment.

Francisco Ponce, director of Barrow’s Center for Neuromodulation and Neurosurgery Residency Program, declined to comment on Neuralink but said Barrow was well-positioned to conduct such implant research because of its long track record in the field.

The FDA declined to comment on Neuralink’s efforts to find a partner for its clinical trials.

Neuralink’s latest efforts come as it faces two known US federal probes into its practices.

The US Department of Agriculture’s Inspector General began looking into potential animal-welfare violations at Neuralink last year. Current and former employees have detailed concerns to Reuters about the company’s rushed animal experiments, resulting in needless suffering and deaths.

The US Department of Transportation has said it is investigating the potential mishandling of hazardous pathogens during the company’s partnership on animal trials with University of California, Davis between 2018 and 2020.

Barrow has helped standardize brain implant surgeries in which the patient can remain asleep, a key step in making it more acceptable to a broad set of the population, Ponce said.

This is in line with Musk’s vision for Neuralink’s brain chip. The billionaire CEO of Tesla and majority owner of Twitter has said Neuralink’s brain implants will become as ubiquitous as Lasik eye surgery.

The devices Barrow has been implanting so far are different than Neuralink’s. Barrow works with deep brain stimulation devices, which received FDA approval in 1997 to help reduce Parkinson’s tremors and have been implanted in more than 175,000 patients.

Neuralink’s implant is a brain computer interface (BCI) device, which uses electrodes that penetrate the brain or sit on its surface to provide direct communication to computers. So far, no company has received US approval to bring a BCI implant to the market.

© Thomson Reuters 2023
 


Realme might not want the Mini Capsule to be the defining feature of the Realme C55, but will it end up being one of the phone’s most talked-about hardware specifications? We discuss this on Orbital, the Gadgets 360 podcast. Orbital is available on Spotify, Gaana, JioSaavn, Google Podcasts, Apple Podcasts, Amazon Music and wherever you get your podcasts.
Affiliate links may be automatically generated – see our ethics statement for details.

Check out our Latest News and Follow us at Facebook

Original Source

Synchron Switch Now Lets You Control Your iPhone or iPad Using Brain: All Details

New York-based company Synchron is working on a brain-computer interface (BCI) technology with the goal of enabling patients to control digital devices hands-free. It has created a device named ‘Synchron Switch’ for converting the thoughts of people with paralysis into action. It lets patients control an iPhone or iPad using their brains. With this technology, an array of sensors called Stentrode is inserted into the top of the brain via a blood vessel and is controlled wirelessly using the Synchron Switch from the patient’s chest. The company foots the cost of implanting and maintaining the device. Synchron is the first company to gain approval from the US Food and Drug Administration to run clinical trials on a computer-brain implant.

As per a report by Semafor, Synchron Switch is being used by six patients. Rodney Gorham, a retired software salesman in Australia, is the first ever to use it with an Apple product. Gorham suffers from ALS and he had the device surgically implanted in his brain at Royal Melbourne Hospital.

As mentioned, Stentrode is implanted into the top of the brain via a blood vessel and it is controlled wirelessly using the Synchron Switch from the patient’s chest. Synchron reportedly pays up the cost of inserting and maintaining the device. The company trains Synchron Switch to recognise the brain signal for a foot tap. The report states that Gorham can control his iPad with his Synchron Switch and can send single-word text messages.

Tom Oxley, Synchron’s co-founder and CEO said that this would be the first brain switch input into the device. Oxley said the skills needed to implant the Stentrode are commonplace, adding that implanting a device directly on the brain would require neurosurgery.

If FDA approves the device for widespread use, Oxley believes that technology like Stentrode will benefit people with disabilities.

Synchron, founded in 2016, is a popular name in the brain-computer interface (BCI) field. As per Pitchbook data, it has around 60 employees and has raised about $65 million (roughly Rs. 538 crore) so far from investors. It received FDA clearance for human trials in 2021 and has completed studies on four people in Australia. Many startups are working to embed devices in skulls, similar to Synchron. Inner Cosmos, Epiminder, and Elon Musk’s Neuralink are the key players in space. Neuralink is yet to receive FDA permission for its implant.


Apple launched the iPad Pro (2022) and the iPad (2022) alongside the new Apple TV this week. We discuss the company’s latest products, along with our review of the iPhone 14 Pro on Orbital, the Gadgets 360 podcast. Orbital is available on Spotify, Gaana, JioSaavn, Google Podcasts, Apple Podcasts, Amazon Music and wherever you get your podcasts.
Affiliate links may be automatically generated – see our ethics statement for details.

For the latest tech news and reviews, follow Gadgets 360 on Twitter, Facebook, and Google News. For the latest videos on gadgets and tech, subscribe to our YouTube channel.

Meta India Head Ajit Mohan Resigns, Joins Rival Snap as APAC President

iQoo 11 May Have Received 3C Certification, Specifications Tipped



Check out our Latest News and Follow us at Facebook

Original Source

Elon Musk Said to Approach Brain Chip Startup Synchron About Deal Amid Neuralink Delays

Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter. Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.

Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.

The sources requested anonymity because the matter is confidential.

Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.

The approach comes after Musk, who is also chief executive of electric car maker Tesla and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.

It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.

Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.

Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink’s product. Its goal is to help paralysed patients operate digital devices with their mind alone.

Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.

Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.

Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.

Only two of Neuralink’s eight founders have remained with the company – Musk and implant engineer Dongjin “DJ” Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink’s president last year, is now an investor in Synchron.

Musk has approached Neuralink’s competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.

© Thomson Reuters 2022


Check out our Latest News and Follow us at Facebook

Original Source

Exit mobile version